Cargando…

Paclitaxel Potentiates the Anticancer Effect of Cetuximab by Enhancing Antibody-Dependent Cellular Cytotoxicity on Oral Squamous Cell Carcinoma Cells In Vitro

Administration of cetuximab (C-mab) in combination with paclitaxel (PTX) has been used for patients with head and neck squamous cell carcinoma (SCC) clinically. In this study, we attempted to clarify the molecular mechanisms of the enhancing anticancer effect of C-mab combined with PTX on oral SCC c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sawatani, Yuta, Komiyama, Yuske, Nakashiro, Koh-ichi, Uchida, Daisuke, Fukumoto, Chonji, Shimura, Michiko, Hasegawa, Tomonori, Kamimura, Ryouta, Hitomi-Koide, Masayo, Hyodo, Toshiki, Kawamata, Hitoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503545/ https://www.ncbi.nlm.nih.gov/pubmed/32878053 http://dx.doi.org/10.3390/ijms21176292

Ejemplares similares

Oral squamous cell carcinoma may originate from bone marrow-derived stem cells
por: Hasegawa, Tomonori, et al.
Publicado: (2021)

The mutational spectrum in whole exon of p53 in oral squamous cell carcinoma and its clinical implications
por: Hyodo, Toshiki, et al.
Publicado: (2022)

Effectiveness of cetuximab as preemptive postsurgical therapy for oral squamous cell carcinoma patients with major risk: a single‐center retrospective cohort study
por: Fukumoto, Chonji, et al.
Publicado: (2021)

Surveillance for Patients with Oral Squamous Cell Carcinoma after Complete Surgical Resection as Primary Treatment: A Single-Center Retrospective Cohort Study
por: Fukumoto, Chonji, et al.
Publicado: (2021)

Identification of Binding Proteins for TSC22D1 Family Proteins Using Mass Spectrometry
por: Kamimura, Ryouta, et al.
Publicado: (2021)

Clinical characteristics, treatment methods and prognoses of patients with oral squamous cell carcinoma in Japanese population: a single institution retrospective cohort study
por: Fukumoto, Chonji, et al.
Publicado: (2020)

Primary syphilis with a tongue ulcer mimicking tongue cancer: a case report
por: Fukumoto, Chonji, et al.
Publicado: (2023)

Morphometric and histomorphometric evaluations of high-purity macro/microporous beta-tricalcium phosphate in maxillary sinus floor elevation: preliminary results on a retrospective, multi-center, observational study
por: Fujita, Atsushi, et al.
Publicado: (2021)

Diversity of the Origin of Cancer Stem Cells in Oral Squamous Cell Carcinoma and Its Clinical Implications
por: Fukumoto, Chonji, et al.
Publicado: (2022)

5,10-Methylenetetrahydrofolate reductase (MTHFR) C677T/A1298C polymorphisms in patients with nonsyndromic cleft lip and palate
por: Komiyama, Yuske, et al.
Publicado: (2020)

Determination of the origin of oral squamous cell carcinoma by microarray analysis: Squamous epithelium or minor salivary gland?
por: Kinouchi, Makoto, et al.
Publicado: (2018)

Vesnarinone, a differentiation inducing drug, directly activates p21(waf1) gene promoter via Sp1 sites in a human salivary gland cancer cell line
por: Omotehara, F, et al.
Publicado: (2002)

Co-delivery of paclitaxel and cetuximab by nanodiamond enhances mitotic catastrophe and tumor inhibition
por: Lin, Yu-Wei, et al.
Publicado: (2017)

Haematogenous cytokeratin 20 mRNA as a predictive marker for recurrence in oral cancer patients
por: Kawamata, H, et al.
Publicado: (1999)

Induction of TSC-22 by treatment with a new anti-cancer drug, vesnarinone, in a human salivary gland cancer cell.
por: Kawamata, H., et al.
Publicado: (1998)

Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME
por: Chevalier, Thomas, et al.
Publicado: (2021)

Induction chemotherapy with cetuximab, carboplatin and paclitaxel for the treatment of locally advanced squamous cell carcinoma of the head and neck
por: BAUMAN, JESSICA, et al.
Publicado: (2013)

Weekly vs. 3-weekly paclitaxel, carboplatin, and cetuximab (PCC) in recurrent/metastatic head and neck cancer
por: Geraghty, Leeann, et al.
Publicado: (2021)

Induction of oxidative stress biomarkers following whole-body irradiation in mice
por: Shimura, Tsutomu, et al.
Publicado: (2020)

A tertiary care experience with paclitaxel and cetuximab as palliative chemotherapy in platinum sensitive and nonsensitive in head and neck cancers
por: Noronha, Vanita, et al.
Publicado: (2017)

Combination Treatment With Paclitaxel, Carboplatin, and Cetuximab (PCE) as First-Line Treatment in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma
por: Ueda, Yuri, et al.
Publicado: (2020)

Induction chemotherapy with paclitaxel, carboplatin and cetuximab for locoregionally advanced nasopharyngeal carcinoma: A single-center, retrospective study
por: Takeshita, Naohiro, et al.
Publicado: (2022)

Paclitaxel and cisplatin with or without cetuximab in metastatic esophageal squamous cell carcinoma: a randomized, multicenter phase II trial
por: Lu, Zhihao, et al.
Publicado: (2022)

High Response Rate to Carboplatin-Paclitaxel-Cetuximab and Pembrolizumab in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
por: Chauffert, Bruno, et al.
Publicado: (2023)

Gli1 Haploinsufficiency Leads to Decreased Bone Mass with an Uncoupling of Bone Metabolism in Adult Mice
por: Kitaura, Yoshiaki, et al.
Publicado: (2014)

Low-dose retinoic acid enhances in vitro invasiveness of human oral squamous-cell-carcinoma cell lines
por: Uchida, D, et al.
Publicado: (2001)

Randomized Phase II Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin Vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET Trial)
por: Tsakonas, Georgios, et al.
Publicado: (2020)

Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Suzuki, Shinsuke, et al.
Publicado: (2021)

Radiotherapy Plus Cetuximab for Squamous Cell Carcinoma of the Oral Cavity: A Multicenter Retrospective Study of 79 Patients in Japan
por: Otsuru, Mitsunobu, et al.
Publicado: (2023)

Second-line treatment of recurrent HNSCC: tumor debulking in combination with high-dose-rate brachytherapy and a simultaneous cetuximab-paclitaxel protocol
por: Ritter, M., et al.
Publicado: (2016)

Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck
por: Enokida, Tomohiro, et al.
Publicado: (2018)

Efficacy and Safety of Cetuximab Plus Cisplatin Alone or in Combination With Paclitaxel in Patients With Head and Neck Squamous Cell Carcinoma: A Randomized Trial
por: Zheng, Yanqing, et al.
Publicado: (2021)

Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy
por: Marín-Jiménez, Juan A., et al.
Publicado: (2022)

Evaluating the efficacy of the anticancer drug cetuximab by atomic force microscopy
por: Zhang, Qingrong, et al.
Publicado: (2018)

Lysophosphatidic acid and its receptors LPA(1) and LPA(3) mediate paclitaxel-induced neuropathic pain in mice
por: Uchida, Hitoshi, et al.
Publicado: (2014)

Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP
por: Folprecht, Gunnar, et al.
Publicado: (2020)

TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck
por: Rubió-Casadevall, Jordi, et al.
Publicado: (2023)

Retracted: “Efficacy and Safety of Cetuximab Plus Cisplatin Alone or in Combination With Paclitaxel in Patients With Head and Neck Squamous Cell Carcinoma: A Randomized Trial”
Publicado: (2023)

Radiation affects glutathione redox reaction by reduced glutathione peroxidase activity in human fibroblasts
por: Shimura, Tsutomu, et al.
Publicado: (2021)

Cetuximab in the management of colorectal cancer
por: Lenz, Heinz-Josef
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_po69jrtvmbqolsptd137ponv1c